{
  "docId": "019dd923-622b-71dc-a6d9-fc4318e06f9b",
  "docSlug": "6ded4b1cfe2c",
  "documentTitle": "Bristol-Myers Squibb Company (BMY)",
  "authorId": "03_Starboard_Value",
  "authorName": "Starboard Value",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2019-03-18 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 89,
  "pageCount": 197,
  "prevPage": 88,
  "nextPage": 90,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "Uses a timeline to visualize the gap between historical performance (3 launches in 15 years) and projected performance (10 launches in 8 years).",
  "elementsJson": [
    "headline_text",
    "subtitle_text",
    "bullet_list",
    "timeline_visual",
    "callout_box",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622b-71dc-a6d9-fc4318e06f9b/89",
  "deckHref": "/decks/019dd923-622b-71dc-a6d9-fc4318e06f9b",
  "deckJsonHref": "/decks/019dd923-622b-71dc-a6d9-fc4318e06f9b.json",
  "deckAnchorHref": "/decks/019dd923-622b-71dc-a6d9-fc4318e06f9b#slide-89",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.9,
        "x": 0.05,
        "y": 0.65
      },
      "kind": "callout",
      "text": "Assuming Celgene’s near-term launch products can generate $10.8 billion revenue by 2028, another 5, on average, blockbuster products would be needed to reach Bristol-Myers’ 2028 revenue base case. This means that Bristol-Myers is assuming that Celgene can produce, on average, 10 blockbuster drugs in 8 years...after only producing 3 in the last 15 years! Why should shareholders underwrite such aggressive assumptions and take on so much risk??",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c8e3256b-d47e-473b-b0d5-67312d748c5b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "callout",
      "text": "This means that Bristol-Myers is assuming that Celgene can produce, on average, 10 blockbuster drugs in 8 years...after only producing 3 in the last 15 years!",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-0f18-711c-9ae3-f9de720e253c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "chart",
      "text": "Timeline showing 2005 (Revlimid), 2013 (Pomalyst), 2014 (Otezla) vs 2020E-2028E (10 projected launches)",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bd63aa04-e115-41f0-8682-5ecfb0eb1b84",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "paragraph",
      "text": "In its base case, Bristol-Myers is assuming Celgene can generate blockbuster drugs at a pace completely out-of-line with historical performance, adding substantial risk to the deal.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "087187ec-fcf4-4942-b39d-81891e9325f8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.05,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "Source: Public company filings, Bristol-Myers investor relations, Starboard estimates.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "79f78830-9198-4c90-9444-684e7d723787",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.88
      },
      "kind": "title",
      "text": "Bristol-Myers needs Celgene’s pipeline to churn out blockbusters at an unprecedented rate",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7c055703-752d-4ece-b87c-4f1314c1ef54",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Celgene Has Only Developed 3 Blockbusters In 15 Years, But Bristol-Myers’ Base Case Assumes, On Average, 10 Blockbusters in the Next 8 Years",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c77d2982-cc27-4540-9db8-d432aa7dc78d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "antagonist-introduction",
      "slug": null,
      "matchId": "2c4bb917-3a8e-411c-8c27-b1e33307ff51",
      "evidence": "Frames Bristol-Myers' assumptions as a risk to shareholders.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}